Latest Industry Insights

At SLAS Europe 2024, Technology Networks had the pleasure of speaking with Jeroen Verheyen, CEO of Semarion, to discuss their award-winning work and how technological innovations advance research.

Two winners earned the New Product Award at SLAS Europe 2024: SEED Biosciences’ Dispen3D and Cryologyx’s PlateReady™. Technology Networks spoke with CEO of CryoLogyx Tom Congdon to learn more about their award-winning new product.

Western blotting is a staple technique in many laboratories but can be time consuming and inconsistent. Technology Networks spoke with Harsha Rao to learn more about Stain-Free western blotting and the advantages of total protein normalization.

To learn more about the FDA's pending decision on MDMA-assisted therapy for PTSD, Technology Networks interviewed Dr. Sam Clark, CEO of Terran Biosciences, who leads one of the industry’s largest psychedelic development programs.

At SLAS Europe 2024, Technology Networks had the pleasure of speaking with Tim Dillon, market manager (Nordics) at Mettler-Toledo Rainin, to learn about how more sustainable options can be implemented into scientists’ daily workflows.

Technology Networks joined SCIEX for a discussion about the company’s latest product launches at this year’s ASMS conference.

Dr. Omid Farokhzad, chair and CEO at Seer, discusses how to achieve deep, unbiased and scalable analysis of the proteome at speed at ASMS 2024.

The advent of single-cell analysis has marked a transformative era in the life sciences, particularly in the field of drug development. To delve deeper into the subject, Technology Networks spoke with Dr. Nora Fekete-Drimusz, head of biology at ARRALYZE. We discuss the transformative impact of single-cell analysis on life science research and explore how ARRALYZE's multifunctional single-cell platform can support those working in this area.

We spoke with Dr. Christian Dillon to learn more about degradation-based therapies, the challenges associated with their discovery and how innovative solutions are helping to realize the potential of this promising class of therapeutics.

Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development. The three teams will combine data, software and tuned models to develop custom, purpose-built solutions for drug discovery.